Junjie Li

Junjie Li is a Global Drug Discovery Scientist at Novo Nordisk, a position held since January 2024. Prior to this role, Junjie Li served as a Principal Scientist and later a Senior Scientist in the Internal Medicine Research Unit at Pfizer from August 2019 to December 2023, focusing on early drug discovery in renal and cardiovascular diseases. Junjie Li's academic journey includes a postdoctoral fellowship at Boston University (July 2017 - August 2019), where significant contributions to cancer research involved discovering metabolic reprogramming in chemotherapy-resistant cells and developing a patented diagnostic method, as published in Nature Communications. Previous postdoctoral work at Purdue University (May 2011 - June 2017) included identifying lipid desaturation as a cancer stem cell biomarker. Junjie Li earned a PhD in Biology from Purdue University (2010-2015) and a B.S. in Life Sciences from Peking University (2006-2010).